Current Clinical Studies

Learn more about our currently enrolling clinical studies at dawesfretzinresearch.com/patients

Use the links to the right to view more information about clinical studies by year.

Psoriasis
Sponsor: Novartis
A randomized, double-blind, multicenter study of subcutaneous secukinumab, assessing Psoriasis Area and Severity Index (PASI) response and maintenance of response in subjects with moderate to severe chronic plaque-type psoriasis on either a fixed dose regimen or on a retreatment at start of relapse regimen. 
October 2011 to Present

Atopic Dermatitis
Sponsor: Novartis
A first-in-human study to evaluate safety and tolerability of repeated topical administrations of BPR277 ointment in healthy volunteers, and safety, tolerability, and preliminary efficacy of multiple topical administrations of BPR277 in patients with atopic dermatitis and Netherton syndrome.
October 2011 to Present

Psoriasis
Sponsor: Novartis
A randomized, double-blind, double-dummy, placebo controlled, multicenter study of subcutaneous secukinumab to demonstrate efficacy after twelve weeks of treatment, compared to placebo and etanercept, and to assess the safety, tolerability and long-term efficacy up to one year in subjects with moderate to severe chronic plaque-type psoriasis.
September 2011 to Present

Multiple Sclerosis
Sponsor: Novartis
A 6-month, randomized, active comparator, open-label, multicenter study to evaluate patient outcomes, safety and tolerability of Fingolimod 0.5 mg/day in patients with relapsing remitting multiple sclerosis who are candidates for MS therapy change from previous disease modifying therapy.
July 2011 to Present

Onychomycosis
Sponsor: Hisamitsu Pharmaceutical Co., Inc.
A Randomized, Double-Blind, Parallel-Group, Multicenter, Placebo-Controlled Study of the Safety and Efficacy of HTU-520 in the Treatment of Mild to Moderate Distal Subungual Onychomycosis of the Toenail
June 2011 to Present

Cutaneous Lupus Erythematosus
Sponsor: Celgene Corporation
A Phase 2, Pilot, Multicenter, Sequential, Ascending Dose Study to Evaluate the Preliminary Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CC-11050 in Subjects With Discoid Lupus Erythematosus and Subacute Cutaneous Lupus Erythematosus
June 2011 to Present

Psoriasis
Sponsor: Pfizer
The main objective of this study is to compare the effects of CP-690,550 with the effects of placebo in patients being treated for moderate to severe chronic plaque psoriasis. This one-year study will also evaluate the safety and tolerability of CP-690,550 versus placebo.
May 2011 to Present 

Chronic Idiopathic Urticaria
Sponsor: Genentech
The study is a global Phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of omalizumab administered subcutaneously as an add-on therapy for the treatment of adolescent and adult patients aged 12-75 who have been diagnosed with refractory CIU and who remain symptomatic despite standard-dosed H1 antihistamine treatment.
April 2011 to Present

Psoriasis
Sponsor: Maruho
A randomized, placebo-controlled, double-blind, parallel group, multi-center phase IIb dose finding study of M518101 in plaque psoriasis patients
March 2011 to Present 

Psoriatic Arthritis
Sponsor: Celgene Corporation
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of Two Doses Of Apremilast (CC-10004) In Subjects With Active Psoriatic Arthritis And A Qualifying Psoriasis Lesion
January 2011 to Present

Psoriatic Arthritis
Sponsor: Centocor, Inc
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Anti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis and Previously Treated With Biologic Anti-TNF Agent(s)
November 2010 to Present

Erectile Dysfunction
Sponsor: Eli Lilly & Co.
A Phase II, A Study of LY900010 (LY2452473 + Tadalafil) in the Treatment of Men With Erectile Dysfunction
November 2010 to Present

Psoriasis
Sponsor:Astellas Pharma Inc
APPLES: A Prospective Pediatric Longitudinal Evaluation to Assess the Long-Term Safety of Tacrolimus Ointment for the Treatment of Atopic Dermatitis
June 2010 to Present

Atopic Dermatitis
Sponsor: Novartis
A Prospective 10 Year Observational Registry of Pediatric Subjects (Age Greater Than or Equal to Two to Age Less Than or Equal to 17 Years) With Atopic Dermatitis Who Have Used Pimecrolimus 1% Cream (PEER Registry)
March 2010 to Present

Asthma
Sponsor: GlaxoSmithKline
A Long-Term, Randomized, Double-Blind, Parallel Group Study of Fluticasone Furoate/GW642444 Inhalation Powder Once-Daily and Fluticasone Furoate Inhalation Powder Once-Daily in Subjects With Asthma
March 2010 to Present

Psoriatic Arthritis
Sponsor: Centocor, Inc
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Anti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis
February 2010 to Present

Psoriasis
Sponsor: Abbott Laboratories
A 10-Year, Post-marketing, Observational Study of HUMIRA® (Adalimumab) in Patients With Chronic Plaque Psoriasis (Ps) (ESPRIT Registry)
November 2008 to Present

Psoriasis
Sponsor: Centocor Ortho Biotech Services, LLC.
A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics (PSOLAR Registry)
May 2008 to Present

Psoriasis
Sponsor: Abbott Laboratories
A Phase III Multicenter, Open-Label Continuation Study in Moderate to Severe Chronic Plaque Psoriasis Subjects who Completed a Preceding Psoriasis Study With XXXXX (M016)
March 2008 to Present

Arthritis with Cardiovascular Disease
Sponsor: Pfizer
A Randomized, Double Blind, Parallel-Group Study Of Cardiovascular Safety In Osteoarthritis Or Rheumatoid Arthritis Patients With Or At High Risk For Cardiovascular Disease Comparing Celecoxib With Naproxen And Ibuprofen.
December 2006 to Present

Psoriasis
Sponsor: Amgen, Inc.
Observational Post-Marketing Safety Surveillance Registry of Enbrel (Etanercept) for Treatment of Psoriasis. (OBSERVE)
July 2006 to Present

Psoriasis
Sponsor: Centocor, Inc.
A Phase III Trial Evaluating the Efficacy and Safety of XXXXX in the Treatment of Subjects with Moderate to Severe Plaque-type Psoriasis. (T09)
January 2006 to Present